Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232825 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
NCT05232825 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 236 participants.
The verdict
NCT05232825, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
Interventions
- DRUG Ocrelizumab IV
- DRUG Ocrelizumab SC
- DRUG Methylprednisolone IV
- DRUG Diphenhydramine IV
- DRUG Dexamethasone given orally
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2025-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05232825
The ClinicalTrials.gov registry entry for NCT05232825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ocrelizumab IV is the first listed.
NCT05232825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05232825 about?
NCT05232825 is a clinical study titled "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis". This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or p...
What is the current status of trial NCT05232825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2022-05-03. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT05232825?
The interventions under investigation include: Ocrelizumab IV (DRUG), Ocrelizumab SC (DRUG), Methylprednisolone IV (DRUG), Diphenhydramine IV (DRUG), Dexamethasone given orally (DRUG).
Who is sponsoring clinical trial NCT05232825?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.